Samantha Lynn Inc. Issues Voluntary Nationwide Recall of Reumofan Plus Tablets Due to Undeclared Drug Ingredients

You are subscribed to Recalls, Market Withdrawals and Safety Alerts for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

 

Samantha Lynn Inc. Issues Voluntary Nationwide Recall of Reumofan Plus Tablets Due to Undeclared Drug Ingredients

08/27/2012 07:53 PM EDT

Samantha Lynn Inc. is voluntarily recalling 500 lots of Reumofan Plus Tablets to the consumer level due to findings of undeclared drug ingredients. The Food and Drug Administration (FDA) sample analysis has found the product to contain methocarbamol and diclofenac.

. For detailed information pertaining to this Recalls, Market Withdrawals and Safety Alerts message, please click the link at the beginning of this bulletin.

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? support@govdelivery.com
• Other inquiries? webmail@oc.fda.gov

---

This email was sent to filter@clubhouseb.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420